APO-Easy
Commercial- Indications
- Alzheimer's disease
Company intelligence / Profile preview
Amoneta Diagnostics
Huningue, Grand Est, Franceamoneta-diagnostics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Amoneta Diagnostics has developed a minimally invasive, highly sensitive blood-based biomarker assay that enables early and accurate diagnosis of Alzheimer’s Disease. The company reports reliable clinical results in terms of sensitivity and specificity but does not specify regulatory approval or commercial launch status yet.
- Therapeutic areas
- Neurology
- Modalities
- Diagnostic test (biomarker-based assay)Device (diagnostic device/assay)Blood biomarker detection
- Industry
- Protein Biomarker Diagnostics
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Amoneta Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amoneta Diagnostics.